Statera Financial Statements From 2010 to 2024
| STABDelisted Stock | USD 0.04 0.0003 0.82% |
Check Statera Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Statera Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Statera financial statements analysis is a perfect complement when working with Statera Biopharma Valuation or Volatility modules.
Statera |
Statera Biopharma Company Return On Equity Analysis
Statera Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Statera Biopharma Return On Equity | -2.87 |
Most of Statera Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Statera Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Statera Biopharma has a Return On Equity of -2.8694. This is 88.03% lower than that of the Healthcare sector and 92.13% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Statera Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Statera Biopharma's current stock value. Our valuation model uses many indicators to compare Statera Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Statera Biopharma competition to find correlations between indicators driving Statera Biopharma's intrinsic value. More Info.Statera Biopharma is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Statera Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Statera Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Statera Biopharma Financial Statements
Statera Biopharma stakeholders use historical fundamental indicators, such as Statera Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Statera Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Statera Biopharma's assets and liabilities are reflected in the revenues and expenses on Statera Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Statera Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropeniaanemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |